Status:
COMPLETED
Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Liver Cancer
Metastatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
RATIONALE: Learning about quality of life in patients with cancer undergoing embolization may help doctors learn about the side effects of treatment and plan the best treatment. PURPOSE: This clinica...
Detailed Description
OBJECTIVES: Primary * Assess the quality of life (QOL) as defined by the presence or absence of physical, social, emotional, and functional distress in patients with primary or metastatic liver canc...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of primary hepatocellular cancer or metastatic liver cancer
- Planning radioembolization or transcatheter arterial embolization using yttrium Y 90 glass microspheres
- No encephalopathy
- PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Bilirubin ≤ 3 mg/dL
- Able to comply with study procedures
- PRIOR CONCURRENT THERAPY:
- No prior treatment with radioembolization or transcatheter arterial embolization
Exclusion
Key Trial Info
Start Date :
April 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT00739167
Start Date
April 1 2008
End Date
May 1 2010
Last Update
October 16 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, United States, 60611-3013